

Vascular Cognitive Impairment and Dementia (VCID)

Fifth Annual Stanford ADRC / UDall Participant Appreciation Day

11/02/2022

Kyan Younes, MD


Assistant Professor

I have no disclosures

Outline


- Epidemiology of vascular risk, prevalence of vascular brain injury
- Definition of vascular disease
- Overlap between vascular disease and Alzheimer`s disease
- Impact on cognition
- Vascular imaging

Estimated numbers of dementia patients worldwide




Future risk of stroke or dementia at age 65

Women





Men






What is cerebrovascular disease?

- Any disorder of cerebral blood vessels
 - Arteriolarsclerosis
 - Atherosclerosis
 - Cerebral amyloid angiopathy
 - CADASIL



What is cerebrovascular injury



- Hemorrhage
 - Large (stroke)
 - Microbleeds (clinically silent)
- Infarction – ischemic
 - Large vessel (stroke)
 - Small vessel (clinically silent)
- White matter hyperintensities
- Dilated Perivascular spaces




What are the vascular risk factors?

- Hypertension
- Hyperlipidemia
- Diabetes Miletus
- Smoking
- Drug abuse
- Obesity
- Traumatic brain injury
- Inflammatory or infectious disorders
- Age
- Sex
- Race and ethnicity
- Family history and genetics
- Bleeding disorders/blood thinners
- Sleep apnea
- Pollution

Evolution of the concept of cognitive impairment on vascular bases



Vascular Cognitive Impairment and Dementia (VCID)




Vascular Dementia

Mixed Alzheimer's disease with a vascular component

VCI that does not meet dementia criteria


Post-stroke dementia

Vascular dementia without recent stroke




A group of syndromes that represent a clinico-radiologic and pathological spectrum

The Neurovascular Unit



Heterogenous pathology of dementia

- Multiple interacting and co-occurring pathologies
 - Neurodegenerative
 - Amyloid and tau
 - Lewy Bodies
 - TDP-43
 - Vascular
 - White matter changes
 - Infarcts
 - Microhemorrhages



Kapasi, et al., 2017

Heterogenous pathology of dementia


- Multiple interacting and co-occurring pathologies
 - Neurodegenerative
 - Amyloid and tau
 - Lewy Bodies
 - TDP-43
 - Vascular
 - White matter changes
 - Infarcts
 - Microhemorrhages

Attributable Risk of Alzheimer's Dementia Attributed to Age-Related Neuropathologies

Patricia A. Boyle,^{1,2} Lei Yu,^{1,3} Sue E. Leurgans,^{1,3} Robert S. Wilson,^{1,2,3} Ron Brookmeyer,⁵
Julie A. Schneider,^{1,3,4} and David A. Bennett^{1,3}


ANN NEUROL 2019;85:114-124

Neuropath	Attribution
AD (plaques/tangles)	41%
Lewy Bodies	11%
TDP-43	12%
Athero & Arteriosclerosis	11%
Infarcts	9%
CAA	8%




Kapasi, et al., 2017

Heterogenous pathology of dementia



Schneider 2007

Heterogenous pathology of dementia



Schneider 2007

Much of Late Life Cognitive Decline Is Not due to Common Neurodegenerative Pathologies

Patricia A. Boyle, PhD,^{1,2} Robert S. Wilson, PhD,^{1,2,3} Lei Yu, PhD,^{1,3}
 Alasdair M. Barr, PhD,⁴ William G. Honer, MD,⁵
 Julie A. Schneider, MD,^{1,3,6} and David A. Bennett, MD^{1,3}

ANN NEUROL 2013;74:478-489




FIGURE 3: Variation in cognitive decline explained by the pathologic indices (gray) and the residual, unexplained variation in cognitive decline (white) derived from fully adjusted models. AD = Alzheimer disease; CVD = cerebrovascular disease; LBD = Lewy body disease.

Vascular risk scores

Step 1

Age, y	Points
40–46	0
47–53	3
54–55	4

Step 2

Education, y	Points
0–6	3
7–9	2
>9	0

Step 3

Sex	Points
Men	1
Female	0

Step 4

Cholesterol, mg/dL	Points
<251	0
≥251	2

Step 5

BMI, kg/m ²	Points
<30	0
≥30	2

Step 6

Systolic blood Pressure, mm/Hg	Points
<140	0
>140	2

Predicted 40-year risk of dementia

Total points	40-Year risk, %
0–1	10
2	11
3	15
4	17
5	20
6	21
7	25
8–14	29

Add up points from steps 1 through 6, then look up predicted 40-years risk of dementia.

Vascular risk scores

Step 1

Age, y	Points
40–46	0
47–53	3
54–55	4

Step 2

Education, y	Points
0–6	3
7–9	2
>9	0

Step 3

Sex	Points
Men	1
Female	0

Step 4

Cholesterol, mg/dL	Points
<251	0
≥251	2

Step 5

BMI, kg/m ²	Points
<30	0
≥30	2


Step 6



Systolic blood Pressure, mm/Hg	Points
<140	0
>140	2

Predicted 40-year risk of dementia

Total points	40-Year risk, %
0–1	10
2	11
3	15
4	17
5	20
6	21
7	25
8–14	29


Add up points from steps 1 through 6, then look up predicted 40-years risk of dementia.






Rabin et al. *Annals of Neurology*, 2019

Clark et al. *Alzheimer's & Dementia*, 2019




Rabin et al. Annals of Neurology, 2019




Clark et al. Alzheimer's & Dementia, 2019




White matter hyperintensities



White matter hyperintensity




White matter hyperintensity



Clinical Trials


SPRINT-MIND




No. at risk	0	1	2	3	4	5	6	7	8
Standard treatment	4285	4282	4168	3886	2829	2107	989	87	0
Intensive treatment	4278	4277	4171	3917	2893	2189	1027	93	0

Clinical Trials


SPRINT-MIND





FINGER




The glymphatic system






The glymphatic system



Expanded perivascular spaces (EPVS)





EPVS in Early and Late Age-of-onset AD



In prep

Function and cognition in AD and CO



In prep

Treatment of vascular cognitive impairment and dementia

- Antihypertensive therapy
- Diabetes management
- Statins
- Antithrombotic therapy
- Cholinesterase inhibitors
- Memantine
- Nonpharmacologic therapy

Cardiovascular Disease Deaths: 1950 to 2010

